| Anti-CCR5 Vaccine |
Ref |
Study |
Immunogen/Vector |
Adjuvant//Route/ Schedule |
Biological features |
Limits |
CCR5 auto-
Abs |
[108] |
Preclinical,
macaques
SHIV challenge |
High density Nt
peptides conjugated to
VLPs from BPV-L1
protein.
Homologous, non
conformed macCCR5
sequences were used. |
9 IM inocula with
TiterMax Gold
adjuvant |
Binding to native macCCR5
in vitro SHIV block.
Reduced viral loads and
time to clearance upon IV
infection with a weakly
pathogenic SHIV.
SHIV clearance correlated
with anti-CCR5 antibody
titer and avidity. |
Abs titers were found to
decline over time but
responded to subsequent
boosts.
No vaccinated macaque
escaped challenge, albeit
most of them controlled it. |
| CCR5 Abs |
[110] |
Preclinical,
macaques
SHIV challenge |
Cyclic ECL2
(Arg168-Tyr177+CyscDDR5)
conjugated to
MAP poly-lysin resin |
Immunizations in
Complete (IP, 0,
1wk) and
Incomplete (SC, 6
wk) Freund’s |
Binding to human and
macaque PBMCs.
In vitro block of laboratory
and primary isolates.
Reduction of viral load upon
challenge. |
Infection was partly
controlled but not
prevented. |
| CCR5 Abs |
[111] |
Preclinical,
macaques
Vaginal SIV
challenges |
Nt and cyclic ECL2
peptides in
bacteriophage Qss
VLPs
Homologous
macCCR5 sequences
were used.
. |
4 IM priming
(Freund’s)
+ 3 vaginal
boosting |
Viremia peak 30-fold lower
Undetectable SIV in 3/12
animals since 6 wk p.i. for
more than a year in serum,
lymph nodes and colon
biopsies.
Viral control due to humoral
but no to cell-mediated
immunity. |
Vaginal secretions could
not be examined.
IgA were not evaluated.
High dose challenges
could have even masked
the real extent of
protection |
